Rhian Gabe, PhD, presented “TRANSFORM National UK Trial of Prostate Cancer Screening” during the 9th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 15, 2025.
How to cite: Gabe, Rhi. “TRANSFORM National UK Trial of Prostate Cancer Screening.” September 15, 2025. Accessed Apr 2026. https://grandroundsinurology.com/transform-national-uk-trial-of-prostate-cancer-screening/
TRANSFORM National UK Trial of Prostate Cancer Screening – Summary
Rhian Gabe, PhD, Professor of Biostatistics and Clinical Trials at Queen Mary University of London, London, United Kingdom, outlines the TRANSFORM trial. TRANSFORM will be conducted in two stages over 19 years. Stage one, now in setup, will run pilot studies of four screening pathways to evaluate feasibility, uptake, and short-term outcomes.
Participants will be divided into four groups, with different intervention paths:
- Prostate-specific antigen (PSA) ≥3 ng/mL followed by bi-parametric magnetic resonance imaging (MRI)
- PSA ≥1 ng/mL followed by MRI
- Universal MRI regardless of prostate-specific antigen (PSA)
- Polygenic risk score–based selection for MRI, using a ≥3.5 percent 10-year risk threshold.
Primary outcomes in stage one include uptake, detection of intermediate-risk cancers, and biopsy and low-risk cancer detection rates. Cost-effectiveness modeling will also be performed.
Dr. Gabe emphasized that TRANSFORM will provide critical evidence for UK screening policy, while contributing to the global evaluation of risk-stratified prostate cancer screening.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Rhian Gabe, MSE, PhD, is a Professor of Biostatistics and Clinical Trials at Wolfson Institute of Population Health in London, England. Dr. Gabe’s research interests include trials and cancer screening, prevention and early detection. She is the lead statistician for studies evaluating interventions for prostate cancer detection and the implementation of low dose CT screening delivered through mobile vans in the community for people at high risk of lung cancer.
